Malaria & Products

MALARIA & PRODUCTS

Antimalarial Medicines and Malaria Solutions

Fosun Pharma has a long-standing presence in antimalarial medicine development and supply. Its portfolio includes products associated with uncomplicated malaria treatment, severe malaria intervention and seasonal malaria chemoprevention.

01

D-ARTEPP®

02

D-ARTEPP® Dispersible

03

SPAQ-CO® Dispersible

04

Artesun®

05

Argesun®

Highlights

MORE MALARIA FREE DAYS
HAVE IT IN EMPTY STOMACH
ONCE(TWO TABLETS) DAILY DOSAGE FOR THREE DAYS
SUPERIOR COMPLIANCE WITH FEWER SIDE EFFECTS.
D-ARTEPP®

Dihydroartemisinin / Piperaquine
for Uncomplicated Malaria

D-ARTEPP® is a dihydroartemisinin/piperaquine pharmaceutical product. Its approved indication, formulation, dosing, administration, contraindications, warnings, interactions and other medical information must be read from the applicable current approved product information.

WHO PREQUALIFICATION

Product-Specific WHO Records

WHO Prequalification records for Guilin Pharmaceutical Co. Ltd. list specific dihydroartemisinin/piperaquine finished pharmaceutical products.

Product-specific WHO records should be cited by reference number and date rather than applying one date to all strengths.

Active ingredients Dihydroartemisinin
Piperaquine
Form Film-coated tablets
Reference MA131 · MA140 · MA151
Revision February 2025
01

40 mg / 320 mg

Dihydroartemisinin 40 mg and piperaquine phosphate 320 mg.

02

60 mg / 480 mg

Dihydroartemisinin 60 mg and piperaquine phosphate 480 mg.

03

80 mg / 640 mg

Dihydroartemisinin 80 mg and piperaquine phosphate 640 mg.

CLINICAL PARTICULARS

Important Product Information

Therapeutic indications

D-ARTEPP® is indicated for the treatment of uncomplicated malaria in adults, children and infants. It is active against all Plasmodium parasites that cause malaria in humans.

Consideration should be given to official guidance on the appropriate use of antimalarial medicinal products.

Posology and administration

D-ARTEPP® should be administered over three consecutive days for a total of three doses taken at the same time each day.

Dosing should be based on body weight as shown in the supplied SmPC.

Contraindications

Contraindications include hypersensitivity to the active substances or excipients, severe malaria according to the WHO definition, certain QTc-related conditions, clinically relevant bradycardia, predisposing cardiac conditions, electrolyte disturbances and use of medicinal products known to prolong the QTc interval.

Warnings and precautions

D-ARTEPP® Tablets should not be used to treat complicated malaria.

The long half-life of piperaquine, about 22 days, should be considered if another antimalarial agent is started because of treatment failure or a new malaria infection.

PHARMACEUTICAL PARTICULARS

Product & Manufacturer Information

Pharmaceutical form

Blue round or capsule-shaped film-coated tablets, depending on strength.

Shelf life

24 months.

Storage

Store in tightly closed containers, protected from light and moisture, not above 25°C.

Manufacturer

Guilin Pharmaceutical Co., Ltd.
No. 43 Qilidian Road, Guilin,
Guangxi, China

03 / D-ARTEPP® DISPERSIBLE

D-ARTEPP® Dispersible

Dihydroartemisinin / Piperaquine Dispersible Tablets

D-ARTEPP® Dispersible is indicated for the treatment of uncomplicated malaria in adults, children and infants 6 months and over and weighing 5kg or more.

It is active against all Plasmodium parasites that cause malaria in humans.

20 mg / 160 mg Dihydroartemisinin / Piperaquine phosphate
30 mg / 240 mg Dihydroartemisinin / Piperaquine phosphate
40 mg / 320 mg Dihydroartemisinin / Piperaquine phosphate

Administration

D-ARTEPP® Dispersible should be administered over three consecutive days for a total of three doses taken at the same time each day.

The tablets should be dispersed in drinking water before administration. Each tablet should be dispersed in a minimum of 10 mL water; the maximum volume of water recommended for dispersion of a dose is 50 mL.

04 / WHO MFT CONTEXT

Multiple First-Line Therapies for Uncomplicated Malaria

The World Health Organization's 2024 implementation guide describes multiple first-line therapies (MFT) as an approach to help address antimalarial drug resistance.

The guide's Nigeria section states that four ACTs are recommended for treating uncomplicated P. falciparum malaria: artemether–lumefantrine (AL), artesunate–amodiaquine (ASAQ), dihydroartemisinin–piperaquine (DHA-PPQ) and artesunate–pyronaridine (ASPY).

01 Artemether–Lumefantrine AL
02 Artesunate–Amodiaquine ASAQ
03 Dihydroartemisinin–Piperaquine DHA-PPQ
04 Artesunate–Pyronaridine ASPY

D-ARTEPP® is a DHA-PPQ product. Its inclusion in an MFT context should not be presented as WHO endorsement of the D-ARTEPP® trade name.

NIGERIA MALARIA CASE-MANAGEMENT CONTEXT

Malaria Case Management

The WHO guide states that Nigeria's national malaria treatment guidelines were last updated in 2020. Malaria diagnosis requires confirmation with an RDT or microscopy.

The guide reports that about 95% of suspected cases in the public sector and 74% in the formal private sector were tested.

The 2021 therapeutic efficacy study indicated that all four registered ACTs were highly efficacious, while the guide notes that, in clinical practice, the effectiveness of AL appeared suboptimal.

Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine (SPAQ) reached approximately 28 million children in 2023.

WHO SOURCE

Multiple first-line therapies as part of the response to antimalarial drug resistance: an implementation guide, Geneva: World Health Organization; 2024.

05 / PHARMACOVIGILANCE

Pharmacovigilance & Drug Safety

Patient safety continues throughout the product lifecycle. Fosun Pharma supports pharmacovigilance and product-safety activities within its pharmaceutical market-access operations.

01 Adverse-event reporting
02 Product-safety monitoring
03 Regulatory safety reporting
04 Product-quality monitoring
05 Post-marketing surveillance
06 Safety-related regulatory coordination
REPORT AN ADVERSE EVENT OR PRODUCT QUALITY CONCERN

Product Safety Information

Patients, healthcare professionals and other stakeholders should use the appropriate official country-specific reporting channels for adverse events, product-quality concerns and medical information requests.

Reporting contacts and procedures should always be taken from the current approved local product information or designated pharmacovigilance channel.

Product indications, formulations, regulatory status, availability and approved use vary by country. Always refer to the latest country-specific approved product information.

MALARIA & PRODUCTS

Explore Our Pharmaceutical Portfolio

Contact Our Team